EA200700871A1 - Способы нейропротекции - Google Patents
Способы нейропротекцииInfo
- Publication number
- EA200700871A1 EA200700871A1 EA200700871A EA200700871A EA200700871A1 EA 200700871 A1 EA200700871 A1 EA 200700871A1 EA 200700871 A EA200700871 A EA 200700871A EA 200700871 A EA200700871 A EA 200700871A EA 200700871 A1 EA200700871 A1 EA 200700871A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- group
- phenyl
- alkyl
- moreover
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
Abstract
Изобретение направлено на обеспечение нейропротекции, включающей введение пациенту терапевтически эффективного количества соединения, выбранного из группы, состоящей из формулы (I) и формулы (II), или его фармацевтически приемлемой соли или сложного эфирав которых фенил замещен в положении Х атомами галогена числом от одного до пяти, выбранными из группы, состоящей из фтора, хлора, брома и йода; и R, R, R, R, Rи Rнезависимо выбраны из группы, состоящей из водорода и С-С-алкила; причем С-С-алкил в случае необходимости замещен фенилом (причем фенил в случае необходимости замещен заместителями, независимо выбранными из группы, состоящей из галогена, С-С-алкила, С-С-алкокси, амино, нитро и циано).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61940204P | 2004-10-15 | 2004-10-15 | |
US69840305P | 2005-07-12 | 2005-07-12 | |
PCT/US2005/036695 WO2006044472A1 (en) | 2004-10-15 | 2005-10-14 | Carbamate compounds for use in treating neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200700871A1 true EA200700871A1 (ru) | 2007-10-26 |
Family
ID=35840528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200700871A EA200700871A1 (ru) | 2004-10-15 | 2005-10-14 | Способы нейропротекции |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1802294A1 (ru) |
JP (1) | JP2008516961A (ru) |
KR (3) | KR20070085309A (ru) |
AU (1) | AU2005295787A1 (ru) |
BR (1) | BRPI0516112A (ru) |
CA (1) | CA2584854A1 (ru) |
EA (1) | EA200700871A1 (ru) |
EC (1) | ECSP077395A (ru) |
IL (1) | IL182432A0 (ru) |
MX (1) | MX2007004491A (ru) |
NI (1) | NI200700094A (ru) |
NO (1) | NO20072444L (ru) |
SG (1) | SG142306A1 (ru) |
WO (1) | WO2006044472A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
KR20190081385A (ko) | 2017-12-29 | 2019-07-09 | 강원대학교산학협력단 | 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
KR20230044274A (ko) | 2020-08-31 | 2023-04-03 | (주)바이오팜솔루션즈 | 신경퇴행성 질환의 예방 또는 치료용 페닐 알킬 카바메이트 화합물 |
CA3191081A1 (en) | 2020-09-10 | 2022-03-17 | Yong Moon Choi | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
US20010034365A1 (en) * | 1996-01-16 | 2001-10-25 | Choi Yong Moon | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
WO2001013904A2 (en) * | 1999-08-20 | 2001-03-01 | Ortho-Mcneil Pharmaceutical, Inc. | Composition comprising a tramadol material and an anticonvulsant drug |
CN1235579C (zh) * | 2001-02-27 | 2006-01-11 | 奥索-麦克尼尔药品公司 | 用于预防或治疗神经变性疾病的氨基甲酸酯化合物 |
JP2008513466A (ja) * | 2004-09-16 | 2008-05-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇発生および癲癇を処置するための2−フェニル−1,2−エタンジオール(di)カルバメートの使用 |
-
2005
- 2005-10-14 EA EA200700871A patent/EA200700871A1/ru unknown
- 2005-10-14 EP EP05810159A patent/EP1802294A1/en not_active Withdrawn
- 2005-10-14 NI NI200700094A patent/NI200700094A/es unknown
- 2005-10-14 KR KR1020077010744A patent/KR20070085309A/ko active Application Filing
- 2005-10-14 AU AU2005295787A patent/AU2005295787A1/en not_active Abandoned
- 2005-10-14 KR KR1020117007395A patent/KR20110049901A/ko not_active Application Discontinuation
- 2005-10-14 BR BRPI0516112-6A patent/BRPI0516112A/pt not_active IP Right Cessation
- 2005-10-14 CA CA002584854A patent/CA2584854A1/en not_active Abandoned
- 2005-10-14 JP JP2007536843A patent/JP2008516961A/ja active Pending
- 2005-10-14 SG SG200802877-1A patent/SG142306A1/en unknown
- 2005-10-14 WO PCT/US2005/036695 patent/WO2006044472A1/en active Application Filing
- 2005-10-14 MX MX2007004491A patent/MX2007004491A/es unknown
- 2005-10-14 KR KR1020097019737A patent/KR20090130175A/ko active Search and Examination
-
2007
- 2007-04-10 IL IL182432A patent/IL182432A0/en unknown
- 2007-04-13 EC EC2007007395A patent/ECSP077395A/es unknown
- 2007-05-11 NO NO20072444A patent/NO20072444L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2584854A1 (en) | 2006-04-27 |
NO20072444L (no) | 2007-06-14 |
BRPI0516112A (pt) | 2008-08-26 |
WO2006044472A1 (en) | 2006-04-27 |
NI200700094A (es) | 2008-02-11 |
AU2005295787A1 (en) | 2006-04-27 |
KR20110049901A (ko) | 2011-05-12 |
ECSP077395A (es) | 2007-05-30 |
EP1802294A1 (en) | 2007-07-04 |
JP2008516961A (ja) | 2008-05-22 |
SG142306A1 (en) | 2008-05-28 |
KR20070085309A (ko) | 2007-08-27 |
MX2007004491A (es) | 2007-08-08 |
KR20090130175A (ko) | 2009-12-18 |
IL182432A0 (en) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200800294A1 (ru) | Способы нейропротекции | |
NO20071921L (no) | Fremgangsmater for behandling av epileptogenese og epilepsi | |
EA200701536A1 (ru) | Способы контроля интервала qt | |
CY1106924T1 (el) | Ενωσεις καρβαμικου για χρηση οσον αφορα την προληψη ή την αγωγη των διαταραχων κινησης | |
NO20080877L (no) | Fremgangsmater for behandling av substansrelaterte forstyrrelser | |
EA200700871A1 (ru) | Способы нейропротекции | |
NO20080739L (no) | Fremgangsmater for behandling av Epileptogenese | |
IL157590A0 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
ATE378046T1 (de) | Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen | |
RS67603A (en) | Carbamate compounds for use in the treatment of pain | |
MX2009004553A (es) | Metodos para el tratamiento de trastornos cocleares y vestibulares. | |
RS67503A (en) | Carbamate compounds for use in preventing of treating psychotic disorders | |
CY1110672T1 (el) | Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης | |
TW200701978A (en) | Methods of treating epileptogenesis and epilepsy | |
MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders |